-
1
-
-
0031927984
-
New approach to classifying non-hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-hodgkin's lymphoma classification project
-
Armitage JO, Weisenburger DD New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's lymphoma classification project. J Clin Oncol 1998; 16: 2780-95.
-
(1998)
J Clin Oncol
, vol.16
, pp. 2780-2795
-
-
Armitage, J.O.1
Weisenburger, D.D.2
-
2
-
-
0027394689
-
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-hodgkin's lymphoma
-
Fisher RI, Gaynor ER, Dahlberg S, et al Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-06.
-
(1993)
N Engl J Med
, vol.328
, pp. 1002-1006
-
-
Fisher, R.I.1
Gaynor, E.R.2
Dahlberg, S.3
-
3
-
-
77949830857
-
Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL
-
Linch DC, Yung L, Smith P., et al Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL. Br J Haematol 2010; 149: 237-43.
-
(2010)
Br J Haematol
, vol.149
, pp. 237-243
-
-
Linch, D.C.1
Yung, L.2
Smith, P.3
-
4
-
-
3242802160
-
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL
-
Pfreundschuh M, Trumper L, Kloess M., et al Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634-41.
-
(2004)
Blood
, vol.104
, pp. 634-641
-
-
Pfreundschuh, M.1
Trumper, L.2
Kloess, M.3
-
5
-
-
79957797972
-
Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-hodgkin's lymphoma: Final results of the Japan clinical oncology group study, JCOG 9809
-
Ohmachi K, Tobinai K, Kobayashi Y., et al Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809. Ann Oncol 2011; 22: 1382-91.
-
(2011)
Ann Oncol
, vol.22
, pp. 1382-1391
-
-
Ohmachi, K.1
Tobinai, K.2
Kobayashi, Y.3
-
6
-
-
3042813710
-
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL
-
Pfreundschuh M, Trumper L, Kloess M., et al Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004; 104: 626-33.
-
(2004)
Blood
, vol.104
, pp. 626-633
-
-
Pfreundschuh, M.1
Trumper, L.2
Kloess, M.3
-
7
-
-
20144369743
-
ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma
-
Reyes F, Lepage E, Ganem G., et al ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005; 352: 1197-205.
-
(2005)
N Engl J Med
, vol.352
, pp. 1197-1205
-
-
Reyes, F.1
Lepage, E.2
Ganem, G.3
-
8
-
-
10744224285
-
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-hodgkin lymphoma
-
Tilly H, Lepage E, Coiffier B., et al Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102: 4284-89.
-
(2003)
Blood
, vol.102
, pp. 4284-4289
-
-
Tilly, H.1
Lepage, E.2
Coiffier, B.3
-
9
-
-
0037165261
-
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
-
Coiffier B, Lepage E, Briere J., et al CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42.
-
(2002)
N Engl J Med
, vol.346
, pp. 235-242
-
-
Coiffier, B.1
Lepage, E.2
Briere, J.3
-
10
-
-
77957200763
-
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the groupe d'Etudes des lymphomes de l'Adulte
-
Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010; 116: 2040-45.
-
(2010)
Blood
, vol.116
, pp. 2040-2045
-
-
Coiffier, B.1
Thieblemont, C.2
Van Den Neste, E.3
-
11
-
-
33745982067
-
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
-
Habermann TM, Weller EA, Morrison V.A., et al Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121-27.
-
(2006)
J Clin Oncol
, vol.24
, pp. 3121-3127
-
-
Habermann, T.M.1
Weller, E.A.2
Morrison, V.A.3
-
12
-
-
38549147027
-
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60)
-
for the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
-
Pfreundschuh M, Schubert J, Ziepert M., et al, for the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9: 105-16.
-
(2008)
Lancet Oncol
, vol.9
, pp. 105-116
-
-
Pfreundschuh, M.1
Schubert, J.2
Ziepert, M.3
-
13
-
-
33646004738
-
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera international trial (MInT) group
-
for the MabThera International Trial (MInT) Group
-
Pfreundschuh M, Trumper L, Osterborg A., et al, for the MabThera International Trial (MInT) Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-91.
-
(2006)
Lancet Oncol
, vol.7
, pp. 379-391
-
-
Pfreundschuh, M.1
Trumper, L.2
Osterborg, A.3
-
15
-
-
9144237554
-
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
-
Hans CP, Weisenburger DD, Greiner T.C., et al Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-82.
-
(2004)
Blood
, vol.103
, pp. 275-282
-
-
Hans, C.P.1
Weisenburger, D.D.2
Greiner, T.C.3
-
16
-
-
77954752069
-
Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab
-
Barrans S, Crouch S, Smith A., et al Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010; 28: 3360-65.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3360-3365
-
-
Barrans, S.1
Crouch, S.2
Smith, A.3
-
17
-
-
0042449063
-
Report of an international workshop to standardize response criteria for non-hodgkin's lymphomas. NCI sponsored international working group
-
Cheson BD, Horning SJ, Coiffier B, et al Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
-
(1999)
J Clin Oncol
, vol.17
, pp. 1244
-
-
Cheson, B.D.1
Horning, S.J.2
Coiffier, B.3
-
18
-
-
84870255805
-
R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma (DLBCL): Final analysis of the LNH03-6B GELA study
-
(abstr)
-
Delarue R, Tilly H, Salles G.A., et al R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma (DLBCL): final analysis of the LNH03-6B GELA study. J Clin Oncol 2012; 30: 8021 (abstr).
-
(2012)
J Clin Oncol
, vol.30
, pp. 8021
-
-
Delarue, R.1
Tilly, H.2
Salles, G.A.3
-
19
-
-
80052980811
-
Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-int) or high IPI grade diffuse aggressive non-hodgkin lymphoma (NHL)
-
(abstr)
-
Stiff PJ, Unger JM, Cook J, et al. Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). J Clin Oncol 2011; 29: 8001 (abstr).
-
(2011)
J Clin Oncol
, vol.29
, pp. 8001
-
-
Stiff, P.J.1
Unger, J.M.2
Cook, J.3
-
20
-
-
34447626101
-
Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: A multicenter study by GITIL (Gruppo Italiano terapie innovative nei linfomi)
-
Tarella C, Zanni M, Di Nicola M, et al Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia 2007; 21: 1802-11.
-
(2007)
Leukemia
, vol.21
, pp. 1802-1811
-
-
Tarella, C.1
Zanni, M.2
Di Nicola, M.3
-
21
-
-
70349128174
-
Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: A phase II multicenter study
-
Vitolo U, Chiappella A, Angelucci E., et al Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. Haematologica 2009; 94: 1250-58.
-
(2009)
Haematologica
, vol.94
, pp. 1250-1258
-
-
Vitolo, U.1
Chiappella, A.2
Angelucci, E.3
-
22
-
-
77958453257
-
High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma
-
Glass B, Ziepert M, Reiser M., et al High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. Ann Oncol 2010; 21: 2255-61.
-
(2010)
Ann Oncol
, vol.21
, pp. 2255-2261
-
-
Glass, B.1
Ziepert, M.2
Reiser, M.3
-
23
-
-
80054723216
-
First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial
-
(abstr)
-
Le Gouill S., Milpied NJ, Lamy T, et al First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial. J Clin Oncol 2011; 29: 8003 (abstr).
-
(2011)
J Clin Oncol
, vol.29
, pp. 8003
-
-
Le Gouill, S.1
Milpied, N.J.2
Lamy, T.3
-
24
-
-
80053385621
-
Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: Final results of the randomized mega-CHOEP trial of the german high-grade non-hodgkin lymphona study group (DSHNHL)
-
(abstr)
-
Schmitz N, Nickelsen M, Ziepert M., et al Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphona Study Group (DSHNHL). J Clin Oncol 2011; 29: 8002 (abstr).
-
(2011)
J Clin Oncol
, vol.29
, pp. 8002
-
-
Schmitz, N.1
Nickelsen, M.2
Ziepert, M.3
-
25
-
-
82255186682
-
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): An open-label randomised phase 3 trial
-
Recher C, Coiffier B, Haioun C., et al Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 2011; 378: 1858-67.
-
(2011)
Lancet
, vol.378
, pp. 1858-1867
-
-
Recher, C.1
Coiffier, B.2
Haioun, C.3
-
26
-
-
82255164025
-
Intensified chemotherapy for diffuse large B-cell lymphomas
-
Vose JM. Intensified chemotherapy for diffuse large B-cell lymphomas. Lancet 2011; 378: 1828-29.
-
(2011)
Lancet
, vol.378
, pp. 1828-1829
-
-
Vose, J.M.1
-
27
-
-
45749152667
-
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers
-
Wilson WH, Dunleavy K, Pittaluga S., et al Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 2008; 26: 2717-24.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2717-2724
-
-
Wilson, W.H.1
Dunleavy, K.2
Pittaluga, S.3
-
28
-
-
79959852471
-
Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: A study from the lunenburg lymphoma biomarker consortium
-
Salles G, de Jong D, Xie W, et al Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 2011; 117: 7070-78.
-
(2011)
Blood
, vol.117
, pp. 7070-7078
-
-
Salles, G.1
De Jong, D.2
Xie, W.3
-
29
-
-
70449589073
-
MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
-
Savage KJ, Johnson NA, Ben-Neriah S, et al MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009; 114: 3533-37.
-
(2009)
Blood
, vol.114
, pp. 3533-3537
-
-
Savage, K.J.1
Johnson, N.A.2
Ben-Neriah, S.3
-
30
-
-
70349575802
-
Lymphomas with concurrent BCL2 and MYC translocations: The critical factors associated with survival
-
Johnson NA, Savage KJ, Ludkovski O, et al Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009; 114: 2273-79.
-
(2009)
Blood
, vol.114
, pp. 2273-2279
-
-
Johnson, N.A.1
Savage, K.J.2
Ludkovski, O.3
-
31
-
-
84855345481
-
B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18) (q32;q21): An aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome
-
Li S, Lin P, Fayad L.E., et al B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol 2012; 25: 145-56.
-
(2012)
Mod Pathol
, vol.25
, pp. 145-156
-
-
Li, S.1
Lin, P.2
Fayad, L.E.3
-
32
-
-
84867060272
-
Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
-
Green TM, Young KH, Visco C, et al Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30: 3460-67.
-
(2012)
J Clin Oncol
, vol.30
, pp. 3460-3467
-
-
Green, T.M.1
Young, K.H.2
Visco, C.3
-
33
-
-
80755143466
-
The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: A bio-CORAL study
-
Thieblemont C, Briere J, Mounier N., et al The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 2011; 29: 4079-87.
-
(2011)
J Clin Oncol
, vol.29
, pp. 4079-4087
-
-
Thieblemont, C.1
Briere, J.2
Mounier, N.3
-
34
-
-
57149089307
-
Stromal gene signatures in large-B-cell lymphomas
-
Lenz G, Wright G, Dave S.S., et al Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359: 2313-23.
-
(2008)
N Engl J Med
, vol.359
, pp. 2313-2323
-
-
Lenz, G.1
Wright, G.2
Dave, S.S.3
-
35
-
-
0034598746
-
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
-
Alizadeh AA, Eisen MB, Davis R.E., et al Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.
-
(2000)
Nature
, vol.403
, pp. 503-511
-
-
Alizadeh, A.A.1
Eisen, M.B.2
Davis, R.E.3
|